Inovio Pharmaceuticals Revenue and Competitors

Location

$446.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Inovio Pharmaceuticals's estimated annual revenue is currently $6.5M per year.(i)
  • Inovio Pharmaceuticals's estimated revenue per employee is $28,472
  • Inovio Pharmaceuticals's total funding is $446.4M.
  • Inovio Pharmaceuticals's current valuation is $999.3M. (January 2022)

Employee Data

  • Inovio Pharmaceuticals has 229 Employees.(i)
  • Inovio Pharmaceuticals grew their employee count by -22% last year.

Inovio Pharmaceuticals's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CFOReveal Email/Phone
3
VP, Intellectual PropertyReveal Email/Phone
4
General CounselReveal Email/Phone
5
VP, Engineering OperationsReveal Email/Phone
6
EVP and General CounselReveal Email/Phone
7
VP, Financial Planning & Analysis and AccountingReveal Email/Phone
8
VP Global CommercialReveal Email/Phone
9
VP, Device QualityReveal Email/Phone
10
SVP, Regulatory AffairsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M100%N/AN/A
#2
$4M2613%N/AN/A
#3
$0.9M6-14%N/AN/A
#4
$1.1M70%N/AN/A
#5
$10.9M703%N/AN/A
#6
$0.7M929%N/AN/A
#7
$4M26-16%N/AN/A
#8
$1.7M1122%N/AN/A
#9
$7.6M492%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Inovio Pharmaceuticals?

Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery, development, and delivery of DNA vaccines with a focus on cancers and infectious diseases. The company’s SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include human papillomavirus/cervical cancer (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), and hepatitis C virus and human immunodeficiency virus vaccines. It is also advancing preclinical research and clinical development for a seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.

keywords:N/A

$446.4M

Total Funding

229

Number of Employees

$6.5M

Revenue (est)

-22%

Employee Growth %

$999.3M

Valuation

N/A

Accelerator

Inovio Pharmaceuticals News

2022-04-19 - Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors

Shares of Inovio Pharmaceuticals Inc. INO, -1.77% slid 1.77% to $2.77 Wednesday, on what proved to be an all-around mixed trading session...

2022-04-17 - Inovio Pharmaceuticals Inc. stock falls Tuesday, underperforms market

Shares of Inovio Pharmaceuticals Inc. INO, -4.73% slipped 4.73% to $2.82 Tuesday, on what proved to be an all-around poor trading session...

2022-04-17 - Inovio Pharmaceuticals Inc. stock outperforms market on strong trading day

Inovio Pharmaceuticals Inc. stock outperforms market on strong trading day. Published: April 25, 2022 at 4:59 p.m. ET. By. MarketWatch Automation.

2021-11-05 - INOVIO Expands Executive Leadership to Prepare for Commercial Operations

PLYMOUTH MEETING, Pa., Nov. 5, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the strategic appointments o ...

2021-11-03 - INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India

PLYMOUTH MEETING, Pa., Nov. 3, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases, and help treat cancer, and HPV-associated diseases, today announced that it has receive ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$69.2M2334%N/A
#2
$36.4M23913%$1.1B
#3
$39.2M2970%N/A
#4
$109.9M3466%N/A
#5
$137M40612%N/A